scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. A Phase II Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma
Search Results
Cancer Hospital and Solove Research Institute, and The University of Texas MD Anderson Cancer Center This is a bi-institutional, dose-escalation phase I trial that studies the side effects and maximum tolerated dose of dabrafenib (GSK2118436) and
targeted therapy in melanoma. Twenty patients with advanced, operable B-RAF mutation-positive melanoma will receive dabrafenib for 2 weeks, followed by the combination of dabrafenib and trametinib for 2 weeks, followed by surgical resection of the disease
scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC
John A. Thompson
stage IV M1b or M1c disease, “the differences go away,” he noted. Molecularly Targeted Therapy With half of patients with metastatic melanoma harboring an activating mutation in BRAF , therapies targeting this mutation—vemurafenib and dabrafenib
Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh
agents (ie, vemurafenib, dabrafenib, and ipilimumab) demonstrated significantly improved response rates and outcomes compared with conventional therapies. Subsequently, a number of ongoing or recently completed phase II and III trials testing new
John A. Thompson
) ipilimumab, dabrafenib plus trametinib, pembrolizumab, and nivolumab. The updated NCCN Guidelines for Melanoma elevate the anti-programmed death protein receptor-1 (PD-1) agents to the frontline setting for metastatic or unresectable disease. Anti-PD-1
Dwight H. Owen, Bhavana Konda, Jennifer Sipos, Tom Liu, Amy Webb, Matthew D. Ringel, Cynthia D. Timmers, and Manisha H. Shah
-mutated PTC demonstrated a response rate of 35%. 7 Resistance to BRAF inhibition is likely to develop eventually, which has been demonstrated in melanoma, and is thought to occur through reactivation of the MAPK pathway. 8 Combination dabrafenib
Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski
markers is currently limited for advanced thyroid cancers, recent data have shown that the BRAF inhibitors vemurafenib and dabrafenib can be effective treatment options for DTC harboring the BRAF V600E mutation. 54 – 56 Because this mutation is common
John A. Thompson
patients. The most recent major trial of the BRAF inhibitor vemurafenib showed an overall response rate of 53%, a median PFS of almost 7 months, and a median OS approaching 16 months. 7 The BRAF inhibitor dabrafenib produced a 50% response rate in a
